About: COVID‐19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID‐19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID‐19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network
Creator	Li, Yan Chen, Chen-Huan Mbbs, Chia Md, Park Wang, Ji-Guang Jam, \| Kario, Kazuomi Morisawa, Yuji Sukonthasarn, \| Sungha, \| Tay, Chin Turana, Yuda Wang, Tzung-Dau Yook-Chin, \|
source	Medline; PMC
abstract	There are several risk factors for worse outcomes in patients with coronavirus 2019 disease (COVID‐19). Patients with hypertension appear to have a poor prognosis, but there is no direct evidence that hypertension increases the risk of new infection or adverse outcomes independent of age and other risk factors. There is also concern about use of renin‐angiotensin system (RAS) inhibitors due to a key role of angiotensin‐converting enzyme 2 receptors in the entry of the SARS‐CoV‐2 virus into cells. However, there is little evidence that use of RAS inhibitors increases the risk of SARS‐CoV‐2 virus infection or worsens the course of COVID‐19. Therefore, antihypertensive therapy with these agents should be continued. In addition to acute respiratory distress syndrome, patients with severe COVID‐19 can develop myocardial injury and cytokine storm, resulting in heart failure, arteriovenous thrombosis, and kidney injury. Troponin, N‐terminal pro‐B‐type natriuretic peptide, D‐dimer, and serum creatinine are biomarkers for these complications and can be used to monitor patients with COVID‐19 and for risk stratification. Other factors that need to be incorporated into patient management strategies during the pandemic include regular exercise to maintain good health status and monitoring of psychological well‐being. For the ongoing management of patients with hypertension, telemedicine‐based home blood pressure monitoring strategies can facilitate maintenance of good blood pressure control while social distancing is maintained. Overall, multidisciplinary management of COVID‐19 based on a rapidly growing body of evidence will help ensure the best possible outcomes for patients, including those with risk factors such as hypertension.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1111/jch.13917
bibo:pmid	32643874
has license	no-cc
sha1sum (hex)	b82c55d1dc6fde3f1c3fcbe2e3f61717597b12df
schema:url	https://doi.org/10.1111/jch.13917
resource representing a document's title	COVID‐19 and hypertension—evidence and practical management: Guidance from the HOPE Asia Network
has PubMed Central identifier	PMC7361740
has PubMed identifier	32643874
schema:publication	J Clin Hypertens (Greenwich)
resource representing a document's body	covid:b82c55d1dc6fde3f1c3fcbe2e3f61717597b12df#body_text
is schema:about of	named entity 'COVID-19' named entity 'injury' named entity 'management' named entity 'Other' named entity 'acute respiratory distress syndrome' named entity 'risk' named entity 'Therefore' named entity 'psychological well-being' named entity 'Troponin' named entity 'risk factors' named entity 'patients' named entity 'evidence' named entity 'myocardial' named entity 'virus' named entity 'disease' named entity 'good health' named entity 'Asia' named entity 'risk factors' named entity 'thrombosis' named entity 'SARS-CoV-2' named entity 'N-terminal' named entity 'COVID' named entity 'B-type natriuretic peptide' named entity 'well-being' named entity 'angiotensin-converting enzyme 2' named entity 'D-dimer' named entity 'infection' named entity 'hypertension' named entity 'acute respiratory distress syndrome' named entity 'risk stratification' named entity 'Myocardial injury' named entity 'COVID-19 pandemic' named entity 'infection' named entity 'regular exercise' named entity 'SARS-CoV-2' named entity 'non-essential' named entity 'high blood pressure' named entity 'COVID-19 deaths' named entity 'older age' named entity 'ACE inhibitors' named entity 'hypertension' named entity 'respiratory diseases' named entity 'holistic approach' named entity 'cardiovascular disease' named entity 'type 1' named entity 'COVID' named entity 'hypertension' named entity 'home blood pressure monitoring' named entity 'infection' named entity 'biomarker' named entity 'cardiovascular disease' named entity 'ARDS' named entity 'infection' named entity 'comorbidity' named entity 'evidence-based' named entity 'ARBs' named entity 'World Hypertension League' named entity 'China' named entity 'older adults' named entity 'post-mortem examinations' named entity 'comorbidities' named entity 'cardiovascular' named entity 'transmembrane serine protease 2' named entity 'SARS-CoV-2' named entity 'coagulation' named entity 'ACE2' named entity 'hypertension' named entity 'hypertension'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software